The Stanley J. Korsmeyer Award
The Stanley J. Korsmeyer Award recognizes the outstanding achievements of ASCI members in advancing knowledge in a specific field and in mentoring future generations of life science researchers. The recognition, which was first known as the ASCI Award, was renamed in 2006 in honor of Dr. Stanley J. Korsmeyer, a dedicated and accomplished physician-scientist and mentor who was the first recipient in 1998 and who passed away in 2005. The recipient of the annual Award is provided with a $20,000 honorarium and presents the Korsmeyer Lecture at the Society’s annual meeting.
2019: Michael S. Diamond, MD, PhD
For his key contributions to understanding the molecular basis of disease caused by globally emerging RNA viruses. More information
2018: Joseph Heitman, MD, PhD
For his key contributions to our understanding of how eukaryotic microbial pathogens evolve, cause disease, and develop drug resistance; and his discovery of TOR and FKBP12 as targets of the immunosuppressive chemotherapeutic drug rapamycin. More information
2017: James E. Crowe Jr., MD
For his research leading to the development of innovative technologies for the isolation and study of antiviral antibodies and for significantly advancing the fields of virology and immunology. More information
2016: Jean-Laurent Casanova, MD, PhD
For his discovery that single-gene inborn errors of immunity can underlie life-threatening infectious diseases in otherwise healthy children and young adults. More information
2015: Louis J. Ptáček, MD
For research leading to the development of the field of ion channel defects, known commonly as channelopathies. More information
2014: Beth Levine, MD
In recognition of fundamental contributions to our understanding of autophagy. More information
2013: Bruce Beutler, MD
In recognition of his contributions to the field of innate immunity. More information
2012: William G. Kaelin, Jr., MD, and Gregg L. Semenza, MD, PhD
In recognition of their contributions to the molecular understanding of cellular oxygen sensing and cellular adaptation to hypoxia. More information
2011: Brian J. Druker, MD, and Charles L. Sawyers, MD
In recognition of their contributions to the development of novel therapeutics in the treatment of leukemia and other forms of cancer. More information
2010: Andrew R. Marks, MD
In recognition of his discoveries that rapamycin inhibits coronary artery stent restenosis, and the role of leaky ryanodine receptor/calcium release channels in heart failure, cardiac arrhythmias and muscular dystrophy. More information
2009: Mitchell A. Lazar, MD, PhD
For his outstanding contributions to our understanding of the transcriptional regulation of metabolism. More information
2008: Gerald I. Shulman, MD, PhD
For his contributions to furthering our understanding of the mechanisms underlying the pathogenesis of type 2 diabetes. More information
2007: D. Gary Gilliland, MD, PhD
For his contributions to the understanding of the genetic basis of human hematological malignancies. More information
2006: Shaun Robert Coughlin, MD, PhD
For his outstanding contributions in the field of signal transduction via thrombin receptors. More information
2005: Francis S. Collins, MD, PhD
For his pioneering efforts in the development of the entire field of human genome research. More information
2004: David Ginsburg, MD
For his contributions to the understanding of the molecular basis of physiologic and pathologic thrombosis and hemostasis. More information
2003: Craig B. Thompson, MD
For his discovery of the critical role costimulatory receptors play in regulating immune responses. More information
2002: Ronald A. DePinho, MD
For fundamental discoveries in cancer research, aging, and chronic degenerative disease. More information
2001: Laurie H. Glimcher, MD
For seminal contributions to our understanding of the transcriptional regulation of lymphocyte subset differentiation.
2000: Christine Edry Seidman, MD
For employing molecular genetic approaches in defining the etiology of inherited human disorders and genetic engineering to produce murine models of human disease, with particular emphasis on heart disease.
Finalists: Jonathan S. Stamler, MD, for elucidating the fundamental role of redox systems in the control of complex physiological responses, using NO-based modification of proteins-in particular S-nitrosylation. Mark T. Keating, MD, for focusing on the molecular genetics of cardiovascular disease, particularly cardiac arrhythmias, cardiomyopathy and obstructive vascular disease.
1999: Richard D. Klausner, MD
For the discovery of key mechanisms that regulate metal metabolism and intracellular trafficking. More information
Finalists: Michael J. Welsh, MD, for discoveries regarding the molecular and cellular pathogenesis of cystic fibrosis. David E. Clapham, MD, PhD, for discoveries regarding the regulation of membrane ion channels, and the physiologic consequences of intracellular calcium signals.
1998: Stanley J. Korsmeyer, MD
For the identification of key genetic mechanisms that govern cell death and survival. More information
Finalists: Peter Agre, MD, for discoveries regarding the roles of water channels in cell membranes. Arthur Weiss, MD, PhD, for discoveries of key signaling pathways in T lymphocytes.